Released May 9, 2016, after the close
10-Q filed May 9, 2016, 39 days after period end · 0001144204-16-099933
Q1 2016 · 10-Q
Revenue$679.00K$679.00K −59.9% vs Q1 2015no prior Q4 2015 on file
Net Income-$8.60M-$8.60M N/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.09-$0.09 N/M vs Q1 2015no prior Q4 2015 on file
Gross Profit$156,000−88.9%
Operating Income-$7,864,000N/M
Operating Cash Flow-$9,625,000N/M
Free Cash Flowderived-$9,876,000N/M
Margins · derived
Gross margin23.0%−60.4 pt vs Q1 2015
Operating margin-1158.2%−840.0 pt vs Q1 2015
Net margin-1266.3%−913.3 pt vs Q1 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2016 | Q1 2015 | Q1 2014 | Q1 2013 |
|---|---|---|---|---|
| Revenue | $679.00K | $1.69M | $6.70M | $3.57M |
| Net Income | -$8.60M | -$5.97M | -$7.35M | -$4.32M |
| EPS Diluted | -$0.09 | -$0.06 | $0.08 | $0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR